Gyre Therapeutics (Gyre Therapeutics) Accounts Payable & Accrued Expense : $19.1 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Accounts Payable & Accrued Expense?

Gyre Therapeutics's quarterly accounts payable & accrued expense increased from Dec. 2021 ($9.8 Mil) to Dec. 2022 ($10.9 Mil) and increased from Dec. 2022 ($10.9 Mil) to Dec. 2023 ($19.1 Mil).

Gyre Therapeutics's annual accounts payable & accrued expense increased from Dec. 2021 ($9.8 Mil) to Dec. 2022 ($10.9 Mil) and increased from Dec. 2022 ($10.9 Mil) to Dec. 2023 ($19.1 Mil).

Gyre Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Gyre Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Accounts Payable & Accrued Expense Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

9.81

10.94

19.11

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
Accounts Payable & Accrued Expense	9.81	10.94	19.11

Gyre Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023